Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galectin Therapeutics

1.68
-0.0800-4.55%
Post-market: 1.740.0600+3.57%19:36 EDT
Volume:197.19K
Turnover:335.95K
Market Cap:105.44M
PE:-2.31
High:1.79
Open:1.75
Low:1.64
Close:1.76
Loading ...

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders

Simply Wall St.
·
14 Mar

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership

Simply Wall St.
·
08 Mar

Galectin Therapeutics Updates Investors on Clinical Trials

TIPRANKS
·
05 Mar

BRIEF-Galectin Therapeutics Inc - Reports Significant Reduction In New Varices With Belapectin

Reuters
·
18 Feb

Galectin Therapeutics’ belapectin shows reduction in new varices

TIPRANKS
·
18 Feb

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

GlobeNewswire
·
18 Feb

Galectin Therapeutics Inc - Navigate Trial Shows 68.1% Reduction in New Varices With Belapectin

THOMSON REUTERS
·
18 Feb

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results

TIPRANKS
·
24 Jan

Galectin Therapeutics Highlights Promising NAVIGATE Trial Results

TIPRANKS
·
13 Jan

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

GlobeNewswire
·
10 Jan

Galectin Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
28 Dec 2024

HC Wainwright Downgrades Galectin Therapeutics to Neutral From Buy

MT Newswires Live
·
28 Dec 2024

H.C. Wainwright downgrades Galectin Therapeutics after MASH trial fails

TIPRANKS
·
28 Dec 2024

Galectin Therapeutics (GALT) was downgraded to a Hold Rating at H.C. Wainwright

TIPRANKS
·
28 Dec 2024

Galectin Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
28 Dec 2024

Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint

Dow Jones
·
21 Dec 2024